SureTrader SureTrader Nadex Advertisement SureTrader
Home > Boards > US OTC > Medical - Drugs >

Elite Pharmaceuticals (ELTP)

ELTP RSS Feed
Add ELTP Price Alert      Hide Sticky   Hide Intro
Moderator: Mocha Jet, Drugdoctor, joseytheoutlawwales, lasers, John_Langston, IB_
Search This Board: 
Last Post: 2/22/2017 5:42:27 AM - Followers: 831 - Board type: Free - Posts Today: 10

Elite Pharmaceuticals is a specialty pharmaceutical company specializing in niche generics and committed to the development of abuse-deterrent opioids to help curb diversion, misuse and abuse.  Elite has a pipeline of opioid abuse-deterrent products under development utilizing the company’s proprietary pharmacological abuse-deterrent technology.

 
Elite’s website can be found by going to http://www.elitepharma.com


How ART Works:

Elite’s proprietary abuse-deterrent technology, ART™, is a multi-particulate capsule which contains an opioid agonist in addition to naltrexone, an opioid antagonist used primarily in the management of alcohol dependence and opioid dependence. When this product is taken as intended, the naltrexone is designed to pass through the body unreleased while the opioid agonist releases over time providing therapeutic pain relief for which it is prescribed. If the multi-particulate beads are crushed or dissolved, the opioid antagonist, naltrexone, is designed to release. The absorption of the naltrexone is intended to block the euphoria by preferentially binding to same receptors in the brain as the opioid agonist and thereby reducing the incentive for abuse or misuse by recreational drug abusers. Elite’s pharmacological approach to abuse-deterrence can be applied to a wide range of opioids used today in pain management.
 


 

Recent Press Releases:

Oct 21, 2015
Elite Pharmaceuticals Announces Positive Top-Line Results From a Pivotal Phase 3 Study for Abuse-Deterrent Opioid ELI-200
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=79416&BzID=2258&t=1948&g=939&Nav=0&LangID=1&s=0

Aug 10, 2015
Elite Pharmaceuticals Reports Record Revenues for First Quarter of Fiscal Year 2016
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=78453&GoTopage=1&Category=2163&BzID=2258&t=1948&G=939

Aug 3, 2015
Elite Pharmaceuticals Completes Enrollment and Dosing for ELI-200 Phase III Efficacy Trial
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=78262&GoTopage=1&Category=2163&BzID=2258&t=1948&G=939

Jun 16, 2015
Elite Pharmaceuticals Granted New Patent for Abuse Deterrent Technology
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=77581&GoTopage=1&Category=2163&BzID=2258&t=1948&G=939

Jun 9, 2015
Elite Pharmaceuticals and Epic Pharma Enter Into a Sales and Distribution Licensing Agreement for Abuse-Deterrent ELI-200
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=77479&BzID=2258&t=1948&g=939&Nav=0&LangID=1&s=0


More information can be found by going to Elite’s investor section:  http://ir.elitepharma.com/press_releases
Highlights From Last Quarter:
 
Second quarter ending September, 2015
Consolidated revenues for the second quarter of fiscal 2015 was $2.7M, all of which came from Elite's generic operation. An increases of 30% over last quarter's generic revenues. Generic revenue continues to grow with new highs being set  8 out of the 10 last quarters. The cost of revenue for this quarter totals $1.4M, for a gross profit of $1.3M. Overall expenses for the quarter total $5.3M with $4.2M going towards the development of Elite’s proprietary abuse-deterrent opioid product,ELI-200.
 
Business Update
The first product to utilize Elite's abuse deterrent technology, ELI-200, has successfully completed Phase III studies. The Company believes that it will be able to file a New Drug Application (NDA) with the FDA during this calendar year. When this application is accepted by the FDA it will be granted expedited review by the FDA,the company estimates that approval could be achieved in calender Q2\2016. Shareholders will be notified when the FDA accepts the ELI-200 NDA which is estimated to be in the first or second week in Jan, 2016.
 
Common shares issued pursuant to the strategic alliance agreement with Epic Investments LLC.
As per the Epic Strategic Alliance, Elite is entitled to 15% of the profits achieved from the commercial sales of Epic's immediate release oxycodone tablets, for a 10 year period commencing on the date of first commercial shipment and Epic is to receive 3 million shares of Common Stock upon approval by the FDA of the ANDA.
 

Financials:
 
 
 

Products:
 
http://www.elitepharma.com/products/

Leadership:

President & Chief Executive Officer - Nasrat Hakim

Nasrat Hakim joined Elite in August 2013 as Director, President and Chief Executive Officer. Mr. Hakim has more than 30 years of pharmaceutical and medical industry experience in Quality Assurance, Analytical Research and Development, Technical Services and Regulatory Compliance. He brings with him proven management experience, in-depth knowledge of manufacturing systems, development knowledge in immediate and extended release formulations and extensive regulatory experience of GMP and FDA regulations. Prior to his leading Elite, from 2004 to 2013, Mr. Hakim was employed by Actavis, Watson and Alpharma in various senior management positions. Most recently, Mr. Hakim served as International Vice President of Quality Assurance at Actavis, overseeing 25 sites with more than 3,000 employees under his leadership. Mr. Hakim also served as Corporate Vice President of Technical Services, Quality and Regulatory Compliance for Actavis U.S., Global Vice President, Quality and Regulatory Compliance for Alpharma, as well as Executive Director of Quality Unit at TheraTech, overseeing manufacturing and research and development. In 2009, Mr. Hakim founded Mikah Pharma, LLC, a virtual, fully functional pharmaceutical company.

Mr. Hakim’s career started in Medical Laboratory Technology from the Academy of Health and Sciences in the U.S. Army based in San Antonio, TX, followed by Graduate Certification in Regulatory Affairs (RAC) from California State University at Sacramento, Sacramento, CA; Bachelor in Chemistry/Bio-Chemistry and Masters of Science in Chemistry from California State University at Sacramento, Sacramento, CA; and a Masters in Law with Graduate Certification in U.S. Taxation from St. Thomas University, School of Law, Miami, FL.

Board of Directors Chairman - Jerry Treppel

Mr. Treppel is currently a Managing Director of ArcLight Advisors, an investment bank specializing in the health care sector. From October 2008 through March 2013, Mr. Treppel was Managing Director of Ledgemont Capital Group LLC, a boutique merchant bank that provided access to capital and corporate advisory services to public and private companies. Additionally, he served as the managing member of Wheaten Capital Management LLC, a capital management company focusing on investments in the health care sector from 2003 to 2008. Over the past 20 years, Mr. Treppel was an equity research analyst focusing on the specialty pharmaceuticals and generic drug sectors at several investment banking firms including Banc of America Securities, Warburg Dillon Read LLC (now UBS), and Kidder Peabody and Co. He previously served as a healthcare services analyst at various firms, including Merrill Lynch & Co. Mr. Treppel holds a BA in Biology from Rutgers College, an MHA in Health Administration from Washington University, and an MBA in Finance from New York University. Mr. Treppel has been a Chartered Financial Analyst *CFA) since 1988.


Investor Relations:

Vice President of Investor Relations and Corporate - Dianne Will

Dianne Will joined Elite in 2003 as an Investor Relations Specialist and was named Elite’s Vice President of Investor Relations and Corporate Affairs in 2013. In 1996, Ms. Will founded Willstar Consultants, an investor relations consulting firm and has been providing investor relations services to a range of public companies for more than 19 years with a primary focus in the pharmaceutical and tech sectors. Her firm provides corporate services including management and execution of investor relations programs, investor communication, peer research, compliance services, support for
management team changes, proxy fights, crisis management and IPOs.

Investor Relations and Corporate Inquiries

Dianne Will
Vice President of Investor Relations and Corporate Affairs
Telephone: 518-398-6222
Email: [email protected]

Corporate Headquarters

165 Ludlow Avenue
Northvale, New Jersey 07647
Phone: 201-750-2646
Fax: 201-750-2755
 


Miscellaneous Links:

SEC Filings: http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001053369&owner=include

FDA website: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails

Clinical Trials.Gov: https://www.clinicaltrials.gov/




 


  Using the industry average PE\Ratio of 15, an over exaggerated  share count of 100% of the 995M authorized shares, and a very conservative
  profit margin of 30%, Elite stands to garner an increase in share price with the launch of each abuse resistant opioid product.

               



  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ELTP
Current Price
Volume:
Bid Ask Day's Range
SureTrader
ELTP News: Current Report Filing (8-k) 02/09/2017 04:46:25 PM
ELTP News: Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) 02/09/2017 04:35:32 PM
ELTP News: Quarterly Report (10-q) 02/09/2017 04:34:39 PM
ELTP News: Current Report Filing (8-k) 12/22/2016 05:25:52 PM
ELTP News: Confidential Treatment Order (ct Order) 12/22/2016 05:17:13 PM
PostSubject
#239843  Sticky Note Maz, this has nothing to do with SequestOx WeeZuhl 01/20/17 08:56:19 PM
#239443  Sticky Note Yes IMO first SequestOx FDA Commercial approval in lasers 01/17/17 11:02:44 PM
#236265  Sticky Note Elite Pharma: The company of firsts: namtae 12/14/16 12:32:00 PM
#234937  Sticky Note THIS IS WHAT YOU NEED TO KNOW BEFORE Couch 11/30/16 03:04:07 PM
#189564  Sticky Note $ELTP SequestOx and ADF Patents lasers 03/18/16 04:29:26 AM
#185967  Sticky Note The only topic here is ELTP. IH Admin [Dan] 02/23/16 09:32:46 PM
#243631   Most definitely $ELTP is negotiating a contract with lasers 02/22/17 05:42:27 AM
#243630   Couch All excellent points and the same conclusions lasers 02/22/17 05:18:46 AM
#243627   Question : is there already a dilution or rob888 02/22/17 04:20:18 AM
#243626   investors are irrational. rob888 02/22/17 04:17:58 AM
#243625   Have you noticed the market SOARING? DOW up stockboy 02/22/17 02:06:12 AM
#243624   No use,Told this board two times to sell Dr_Thorfin 02/22/17 01:51:27 AM
#243623   I live in this world too. NASDAQ you are Bngo 02/22/17 12:33:10 AM
#243622   This has been the case since I came John_Langston 02/22/17 12:32:11 AM
#243621   .1351 wasn't to the low of the day. John_Langston 02/21/17 11:39:13 PM
#243620   I was told ELTP would be at $2 John_Langston 02/21/17 11:35:34 PM
#243619   Fish tale once again. jour_trader 02/21/17 11:17:22 PM
#243618   Good information here Couch! Dubster watching 02/21/17 10:44:06 PM
#243617   Awesome opportunity here. ELTP I just keep adding to Dubster watching 02/21/17 10:42:29 PM
#243615   1.) First ever Immediate Release ADF labeled opiod. NASDAQ2020 02/21/17 10:23:28 PM
#243614   No further Dilution will be needed: NASDAQ2020 02/21/17 10:20:18 PM
#243613   If that helps you sleep at night you Goodtimes93 02/21/17 10:18:07 PM
#243612   no hurry on that accumulation...plenty of time luvwetscent 02/21/17 10:16:18 PM
#243611   Elite on its way to CFP this year. NASDAQ2020 02/21/17 10:15:07 PM
#243610   Sequest Ox bead has been reformulated with a NASDAQ2020 02/21/17 10:14:07 PM
#243609   Gee and yet positive BE SequestOx data will Couch 02/21/17 10:12:34 PM
#243608   10 Pathways to DollarLand NASDAQ2020 02/21/17 10:12:28 PM
#243607   It proves you right to you. Goodtimes93 02/21/17 10:10:32 PM
#243606   Like I said positive SequestOx BE data proves Couch 02/21/17 10:06:35 PM
#243605   First order of SequestOx. NASDAQ2020 02/21/17 10:05:52 PM
#243604   The reality: CC was solid! Elite no longer Couch 02/21/17 10:03:07 PM
#243603   Yeah sure thing - just like the new Couch 02/21/17 10:01:57 PM
#243602   So holding all the way to the bottom Goodtimes93 02/21/17 09:59:32 PM
#243601   Sheesh. In the face of incredible disappointment, conix 02/21/17 09:58:58 PM
#243600   Get ready to do it again, GL NASDAQ2020 02/21/17 09:58:43 PM
#243599   The reality: cc sucked! Stock tanking! Future looks bleak jtf3 02/21/17 09:54:55 PM
#243598   Elite is primed to lose the teens. New 52 namtae 02/21/17 09:54:27 PM
#243597   Just like selling at the top and buying Couch 02/21/17 09:51:40 PM
#243596   Its bounced between $0.135 and $0.18 so many NASDAQ2020 02/21/17 09:50:14 PM
#243595   As lower is in the future then buying Goodtimes93 02/21/17 09:49:53 PM
#243594   By diluting to 1B shares Nasrat is basically jour_trader 02/21/17 09:47:15 PM
#243593   Gee and the 52 week low was .11. Couch 02/21/17 09:45:01 PM
#243592   A lot of Pharas would like to have NASDAQ2020 02/21/17 09:43:34 PM
#243591   Yeah no real investor or trader wants to Couch 02/21/17 09:43:28 PM
#243590   This isn't sideways. This has been a slow jour_trader 02/21/17 09:40:48 PM
#243589   NEVER SELL! Just Buy, Hold and Accumulate! Can conix 02/21/17 09:38:45 PM
#243588   Couch- you should have sold at 97 cents!!! jtf3 02/21/17 09:25:33 PM
#243587   I remember your singing a different tune lol My namtae 02/21/17 09:22:58 PM
#243586   Ok fair enough. The rest of Goodtimes93 02/21/17 09:22:00 PM
#243585   Sorry the rest of the investor base hardly Couch 02/21/17 09:15:12 PM
#243584   Seems the rest of the investor base disagrees Goodtimes93 02/21/17 09:12:27 PM
#243583   Sorry but the lay of the land is namtae 02/21/17 09:11:37 PM
#243582  Restored Thanks but I don't need to make any Couch 02/21/17 09:06:32 PM
#243581   Your thoughts on why Pfizer hasn't launched Troxyca aELmTPa 02/21/17 08:54:21 PM
#243577   Sure okay - just like the shares are Couch 02/21/17 08:21:07 PM
#243576   Not by me but the precipitous walk down Goodtimes93 02/21/17 08:18:25 PM
PostSubject